#Cenrifki #SPMS #multiplesclerosis #relapsingmultiplesclerosis #Sanofi #disabilitytargetingmedicine #nrSPMS #disabilityprogression #EMA #CHMP #HERCULESstudy #MSrelateddisability #brainpenetrantBrutonstyrosinekinaseinhibitor #smoulderingneuroinflammation #SPMSwithoutrelapses
zurl.co/GD1h3
zurl.co/GD1h3
Cenrifki approved in EU for secondary progressive multiple sclerosis - PharmaTimes
Sanofi therapy becomes first disability‑targeting medicine for nrSPMS
pharmatimes.com
June 23, 2026 at 12:43 PM